Hansoh hits near 4-year peak as its cancer drug gets UK marketing approval

Hansoh Pharmaceutical

04/06/2025 06:49

** Shares of Hansoh Pharmaceutical Group 3692.HK rise 3.8% to HK$27.5, their highest levels since August 2021

** Stock marks biggest intraday pct gain since May 20, and on track for a third straight session of rise, if current trend holds

** Stock is fifth-biggest pct gainer on the Hang Seng Commerce & Industry Index .HSNC, which climbs 0.8%

** Hansoh says its innovative drug Aumolertinib Mesilate Tablets for lung cancer has been approved by the Medicines and Healthcare Products Regulatory Agency (MHRA) in the UK for marketing

** The Hang Seng Biotech Index .HSHKBIO rises 3.1% and the Hang Seng Index .HSI adds 0.5%

** YTD, stock up 56.8%

 (Reporting by Donny Kwok)

 ((donny.kwok@thomsonreuters.com))